{
    "clinical_study": {
        "@rank": "124321", 
        "acronym": "RTCAS", 
        "arm_group": [
            {
                "arm_group_label": "under SIT", 
                "description": "patients completed second or third year of SIT. We include the patients directly after last SIT vaccination."
            }, 
            {
                "arm_group_label": "after SIT", 
                "description": "Patients completed three years of SIT for at least three years. We included them as a follow up."
            }, 
            {
                "arm_group_label": "no SIT", 
                "description": "These patients were determined randomly. They have a clinically relevant grass pollen allergy. They never had a SIT."
            }
        ], 
        "biospec_descr": {
            "textblock": "serum"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The primary endpoint was the induction of T-regulatory cells under s specific subcutaneous\n      immunotherapy (SCIT). Patients suffering from grass pollen allergy (relevant clinical\n      symptomes during the pollen season, Skin Prick test diamter >4mm or RAST class II or higher)\n      were included. The patients were allocated to three study groups:\n\n      Group 1: during and directly after SCIT (after completion the 2nd or 3rd year of treatment)\n      Group 2: completed SCIT more then three years ago Group 3: Patients with clinically relevant\n      grass pollen allergy without SCIT.\n\n      The investigators analyzed the lung function parameters, exhaled NO (eNO) and asked the\n      patients to record symptoms during the adjacent pollen season. A blood sample was drawn to\n      analyze the amount of TH1 and TH2 and regulatory T-cells, inflammatory markers(IL-2, IL-5,\n      IL-10, IL-12/23, TNF-alpha, IFN-gamma) and blocking antibodies (IgG, IgG4)."
        }, 
        "brief_title": "Regulatory T-cells After Subcutaneous Immunotherapy", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Grass Pollen Allergy", 
            "Specific Immunotherapy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis, Allergic, Seasonal", 
                "Hypersensitivity"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  informed consent,\n\n          -  clinically relevant grass pollen allergy,\n\n          -  age > 6 and < 28\n\n        Exclusion Criteria:\n\n          -  severe unstable asthma,\n\n          -  regular ingestion of antihistamine,\n\n          -  systemic steroid therapy,\n\n          -  lung funtcion VC < 70%,\n\n          -  FEV1 < 65%"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "28 Years", 
            "minimum_age": "7 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients aged 7-28 years of age with house grass pollen allergy"
            }
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830673", 
            "org_study_id": "FRA-2012-SCIT"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "T-regulatory cells", 
            "TH1, TH2 cells", 
            "specific IgE", 
            "specific IgG", 
            "specific IgG4", 
            "IL2", 
            "IL5", 
            "IL10", 
            "IL12/23", 
            "Y-IFN", 
            "TNF-a"
        ], 
        "lastchanged_date": "April 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Frankfurt/M", 
                    "country": "Germany", 
                    "state": "Hessen", 
                    "zip": "60590"
                }, 
                "name": "Johann Wolfgang Goethe-university"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "3", 
        "official_title": "Investigation of T-regulatory Cells After Subcutaneous Immunotherapy", 
        "overall_official": {
            "affiliation": "Johann Wolfgang Goethe University Hospitals", 
            "last_name": "Stefan Zielen, Prof.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Determination of T-reulatory cells by FACS (staining for fox p3).", 
            "measure": "Induction of regulatory t-cells", 
            "safety_issue": "No", 
            "time_frame": "group 1: on average within one week after 4th injection of SCIT, group 2: more than three years (3-4 years) after SCIT completion, group 3: no specific time point because there was no intervention"
        }, 
        "reference": [
            {
                "PMID": "20624650", 
                "citation": "Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol. 2010 Nov;126(5):942-9. Epub 2010 Jul 10."
            }, 
            {
                "PMID": "12704121", 
                "citation": "Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun. 2003 May;71(5):2498-507."
            }, 
            {
                "PMID": "14572416", 
                "citation": "Drachenberg KJ, Heinzkill M, Urban E, Woroniecki SR. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol Immunopathol (Madr). 2003 Sep-Oct;31(5):270-7."
            }, 
            {
                "PMID": "20345983", 
                "citation": "Rosewich M, Schulze J, Eickmeier O, Telles T, Rose MA, Schubert R, Zielen S. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin Exp Immunol. 2010 Jun;160(3):403-10. doi: 10.1111/j.1365-2249.2010.04106.x. Epub 2010 Mar 16."
            }, 
            {
                "PMID": "20003062", 
                "citation": "Rosewich M, Schulze J, Fischer von Weikersthal-Drachenberg KJ, Zielen S. Ultra-short course immunotherapy in children and adolescents during a 3-yrs post-marketing surveillance study. Pediatr Allergy Immunol. 2010 Feb;21(1 Pt 2):e185-9. doi: 10.1111/j.1399-3038.2009.00953.x. Epub 2009 Dec 8."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830673"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johann Wolfgang Goethe University Hospitals", 
            "investigator_full_name": "Dr. med. Martin Rosewich", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Staining for CD3, CD4, CD183", 
                "measure": "TH1-cells by FACS", 
                "safety_issue": "No", 
                "time_frame": "group 1: on average within one week after 4th injection of SCIT, group 2: more than three years (3-4 years) after SCIT completion, group 3: no specific time point because there was no intervention"
            }, 
            {
                "description": "Staining for CD3, CD4, CD 194", 
                "measure": "Th-2 cells by FACS", 
                "safety_issue": "No", 
                "time_frame": "group 1: on average within one week after 4th injection of SCIT, group 2: more than three years (3-4 years) after SCIT completion, group 3: no specific time point because there was no intervention"
            }, 
            {
                "description": "Cytokines (Il-2, Il-5, Il-10, Il-12/23, IFN-gamma, TNF-alpha) were determined by cytometric bead assay", 
                "measure": "Inflammatory cytokines", 
                "safety_issue": "No", 
                "time_frame": "group 1: on average within one week after 4th injection of SCIT, group 2: more than three years (3-4 years) after SCIT completion, group 3: no specific time point because there was no intervention"
            }, 
            {
                "description": "questionnaire to assess the quality of life (QoL), the clinical symptoms and medication scores during the SCIT adjacent pollen season.", 
                "measure": "Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "During the pollen season - for group 1: pollen season directly after completion of SCIT therapy, group 2: same pollen season as group 1, three years after completion of a 3 year SCIT, group 3: same pollen season as group 1 and 2"
            }
        ], 
        "source": "Johann Wolfgang Goethe University Hospitals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johann Wolfgang Goethe University Hospitals", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}